15.06.2010 • NewsGreeceInsulinNovo Nordisk

Novo Nordisk Says Accepts New Greek Insulin Prices

Denmark's Novo Nordisk, the world's biggest maker of insulin, said on Monday it would supply its modern insulins to Greece again after the country raised prices on the drugs. Drug prices are in the firing line as European governments tackle runaway budget deficits.

Novo in May suspended the supply of its most modern insulins from Greece, calling a government decision to slash some prices by 25% "unacceptable." Novo said in an emailed statement that Greece, late on Friday, issued a new price bulletin, effective June 14, for 48 insulin products including Novo's modern insulins and pen-based insulins.

Novo said the new prices are higher than those dictated by the decree which took effect on May 3, but lower than the average of the three lowest prices in Europe, a level Novo had argued is reasonable.

"However, the government has stated it will base future prices in Greece on the average of the three lowest prices in Europe in an upcoming price decree, which it plans to have in place by Sept. 1 at the latest," it said. "We have therefore accepted the new temporary prices. As a result, we expect that all pharmacies will soon be able to deliver the full range of Novo Nordisk insulin products in Greece," Novo said.

It said on June 10 it would supply drugs as normal again if Greece changed the price formula to use the average from the three countries that out of 22 European nations have the lowest prices.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.